NCCN临床实践指南：免疫疗法相关毒性的管理(2018.V2)中文版

Continue
Anthony J. e Cancer Center
Olalekan Oluwole, MD ‡ Vanderbilt-Ingram Cancer Center
Sandip P. Patel, MD † ‡ Þ UC San Diego Moores Cancer Center
肌肉骨骼毒性 • 炎性关节炎 (IMMUNO-23) • 肌痛/肌炎 (IMMUNO-24)
输液/相关反应 (IMMUNO-25)
免疫抑制原则 (IMMUNO-A)
患者教育原则 (IMMUNO-B) 免疫治疗再激发原则 (IMMUNO-C) 常规监测原则 (IMMUNO-D)
临床试验: NCCN认为任何癌症患者的最 佳治疗是在一项临床试验中。 特别鼓励参与临床试验。 在线寻找NCCN成员机构的临床试验， 点击此处: /clinical_trials/clinicians.aspx.
NCCN指南2018年第2版 免疫治疗相关毒性的管理
NCCN 指南索引 目录 讨论
免疫治疗相关毒性管理NCNN专家组成员 指南更新汇总 皮肤毒性 • 斑丘疹 (IMMUNO-1) • 瘙痒症 (IMMUNO-2) • 皮肤水泡 (IMMUNO-3)
胃肠毒性 (IMMUNO-4)
肝脏毒性 (IMMUNO-5)
Printed by zhang pinliang on 9/21/2018 7:44:02 AM. For personal use only. Not approved for distribution. Copyright © 2018 National Comprehensive Cancer Network, Inc., All Rights Reserved.
Hematology oncology ¤ Gastroenterology Þ Internal medicine ð Endocrinology v Dermatology
# Nursing
X Pulmonary medicine ≡ ASCO committee
member * Discussion Section
NCCN证据与共识等级: 所有的推荐均 是2A类除非另作说明。 见 NCCN 证据 与共识等级。
NCCN指南®是证据的一个说明以及专家们对目前公认治疗方法的观点共识。任何临床医生试图应用或参考NCCN指南应 该在具体的临床情况下独立进行医学判断来确定患者的护理或治疗。国立综合癌症网络®（NCCN®）对任何有关其内 容、使用或应用不作任何告知或担保并且对以任何方式的应用或使用不承担任何责任。NCCN指南版权属于国立肿瘤综 合网络®。版权所有。NCCN指南及图解未经NCCN书面同意不得以任何形式转载。 ©2018.
Marc S. Ernstoff, MD † ≡ Roswell Park Cancer Institute Matthew Frigault, MD † Dana-Farber Cancer Institute | Massachusetts General Hospital Cancer Center Brianna Hoffner, MSN, AOCNP, APRN-BC † # University of Colorado Cancer Center Christopher J. Hoimes, MD † Case Comprehensive Cancer Center/ University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute Mario Lacouture, MD v Memorial Sloan Kettering Cancer Center Frederick Locke, MD † Moffitt Cancer Center Matthew Lunning, DO † ‡ Þ Fred & Pamela Buffett Cancer Center Nisha A. Mohindra, MD † Robert H. Lurie Comprehensive Cancer Center of Northwestern University Jarushka Naidoo, MD † The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Printed by zhang pinliang on 9/21/2018 7:44:02 AM. For personal use only. Not approved for distribution. Copyright © 2018 National Comprehensive Cancer Network, Inc., All Rights Reserved.
NCCN指南2018年第2版 免疫治疗相关毒性的管理
免疫相关毒性管理NCCN指南2018第2版较2018第1版的更新包括： MS-1 • 讨论部分已添加到指南中。反映了工作步骤中的推荐。
NCCN 指南索引 目录 讨论
眼毒性 (IMMUNO-16)
神经系统毒性 • 重症肌无力 (IMMUNO-17) • 格林-巴利综合症 (IMMUNO-18) • 周围神经病 (IMMUNO-19) • 无菌性脑膜炎 (IMMUNO-20) • 脑炎 (IMMUNO-20) • 横贯性脊髓炎 (IMMUNO-21)
心血管毒性 (IMMUNO-22)
NCCN指南2018年第2版 免疫治疗相关毒性的管理
NCCN 指南索引 目录 讨论
*John A. Thompson, MD/Chair † ‡ ≡ Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance *Bryan J. Schneider, MD/Vice-Chair † ≡ University of Michigan Comprehensive Cancer Center *Julie Brahmer, MD/Vice-Chair † ≡ The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Stephanie Andrews, MS, ANP-BC ‡ Moffitt Cancer Center Philippe Armand, MD, PhD ‡ Dana–Farber Cancer Institute Shailender Bhatia, MD † Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance Lihua E. Budde, MD, PhD ‡ City of Hope National Medical Center Luciano Costa, MD, PhD ‡ University of Alabama at Birmingham Comprehensive Cancer Center Marianne Davies, MSN, DNP † Yale Cancer Center/Smilow Cancer Hospital David Dunnington, MA Patient Advocate
Jeffrey A. Sosman, MD ‡ Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Momen Wahidi, MD X Duke Cancer Institute
Yinghong Wang, MD, PhD ¤ ≡ The University of Texas MD Anderson Cancer Center
Writing Committee
Version 2.2018, 09/19/18 © National Comprehensive Cancer Network, Inc. 2018, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
Printed by zhang pinliang on 9/21/2018 7:44:02 AM. For personal use only. Not approved for distribution. Copyright © 2018 National Comprehensive Cancer Network, Inc., All Rights Reserved.
Sunil Reddy, MD † Stanford Cancer Institute
Mabel Ryder, MD ð Mayo Clinic Cancer Center
Bianca D. Santomasso, MD, PhD Memorial Sloan Kettering Cancer Center
NCCN wishes to acknowledge the contributions of ASCO in supporting advisory committees for the development of the Guidelines.
NCCN Guidelines Panel Disclosures
NCCN肿瘤学临床实践指南（NCCN指南®） 与美国临床肿瘤学会（ASCO）合作
免疫治疗相关毒性的管理
（免疫检查点抑制剂相关毒性）
2018第2版—2018年9月19日
Continue
续
Version 2.2018, 09/19/18 © National Comprehensive Cancer Network, Inc. 2018, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
Version 2.2018, 09/19/18 © National Comprehensive Cancer Network, Inc. 2018, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
Jedd Wolchok, MD, PhD † ≡ Memorial Sloan Kettering Cancer Center
NCCN Kristina M. Gregory, RN, MSN, OCN Alyse Johnson-Chilla, MS Jillian Scavone, PhD
† Medical oncology ‡ Hematology/
胰腺毒性 • 淀粉酶/脂肪酶升高 (IMMUNO-7) • 急性胰腺炎 (IMMUNO-8)
内分泌毒性 • 高血糖/糖尿病(IMMUNO-9) • 甲状腺 (IMMUNO-10) • 肾上腺、垂体 (IMMUNO-11) • 垂体炎 (IMMUNO-12)
肺毒性 (IMMUNO-13)
肾毒性 (IMMUNO-15)